[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Tazarotene.]
[J01EC02, sulfadiazine, The metabolism of Tazarotene can be decreased when combined with Sulfadiazine.]
[L02BA01, tamoxifen, The metabolism of Tazarotene can be decreased when combined with Tamoxifen.]
[S03AA02, tetracycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Tetracycline.]
[N04BC07, apomorphine, The metabolism of Tazarotene can be decreased when combined with Apomorphine.]
[R03DA04, theophylline, The metabolism of Tazarotene can be decreased when combined with Theophylline.]
[B01AC05, ticlopidine, The metabolism of Tazarotene can be decreased when combined with Ticlopidine.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Tazarotene.]
[L01XF01, tretinoin, The metabolism of Tazarotene can be decreased when combined with Tretinoin.]
[R03BA07, mometasone, The metabolism of Tazarotene can be decreased when combined with Mometasone.]
[N03AC02, trimethadione, The metabolism of Tazarotene can be decreased when combined with Trimethadione.]
[J01EA01, trimethoprim, The metabolism of Tazarotene can be decreased when combined with Trimethoprim.]
[L02BX03, abiraterone, The metabolism of Tazarotene can be decreased when combined with Abiraterone.]
[J05AG05, rilpivirine, The metabolism of Tazarotene can be decreased when combined with Rilpivirine.]
[C08DA01, verapamil, The metabolism of Tazarotene can be decreased when combined with Verapamil.]
[S01XA02, vitamin A, The risk or severity of adverse effects can be increased when Vitamin A is combined with Tazarotene.]
[J05AF01, zidovudine, The metabolism of Tazarotene can be decreased when combined with Zidovudine.]
[L01EC01, vemurafenib, The metabolism of Tazarotene can be decreased when combined with Vemurafenib.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Tazarotene.]
[L02BB04, enzalutamide, The metabolism of Tazarotene can be decreased when combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Tazarotene can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The metabolism of Tazarotene can be decreased when combined with Teriflunomide.]
[L01EX07, cabozantinib, The metabolism of Tazarotene can be decreased when combined with Cabozantinib.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Tazarotene.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Tazarotene.]
[A06AX06, tegaserod, The metabolism of Tazarotene can be decreased when combined with Tegaserod.]
[M01AH01, celecoxib, The metabolism of Tazarotene can be decreased when combined with Celecoxib.]
[L01EC02, dabrafenib, The serum concentration of Tazarotene can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Tazarotene can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Tazarotene.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Tazarotene.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Tazarotene.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Tazarotene.]
[L04AA32, apremilast, The metabolism of Tazarotene can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Tazarotene can be increased when combined with Betamethasone.]
[C10AB02, bezafibrate, The metabolism of Tazarotene can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Tazarotene can be increased when combined with Siltuximab.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Tazarotene.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Tazarotene.]
[L04AC10, secukinumab, The metabolism of Tazarotene can be increased when combined with Secukinumab.]
[A02BC03, lansoprazole, The metabolism of Tazarotene can be decreased when combined with Lansoprazole.]
[J02AC05, isavuconazole, The metabolism of Tazarotene can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Tazarotene.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Tazarotene.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Tazarotene.]
[L04AB02, infliximab, The metabolism of Tazarotene can be increased when combined with Infliximab.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Tazarotene.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Tazarotene.]
[J05AG03, efavirenz, The metabolism of Tazarotene can be decreased when combined with Efavirenz.]
[J05AX18, letermovir, The metabolism of Tazarotene can be decreased when combined with Letermovir.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be decreased when combined with Tazarotene.]
[N03AX24, cannabidiol, The metabolism of Tazarotene can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Tazarotene can be increased when combined with Avatrombopag.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Tazarotene.]
[N03AX17, stiripentol, The metabolism of Tazarotene can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Tazarotene can be increased when combined with Tecovirimat.]
[J01AA13, eravacycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Eravacycline.]
[J01AA14, sarecycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Sarecycline.]
[J01AA15, omadacycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Omadacycline.]
[L04AA39, emapalumab, The metabolism of Tazarotene can be increased when combined with Emapalumab.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Tazarotene.]
[P02BX04, triclabendazole, The metabolism of Tazarotene can be decreased when combined with Triclabendazole.]
[J01AA11, clomocycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Clomocycline.]
[C09CA06, candesartan, The metabolism of Tazarotene can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Tazarotene can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The metabolism of Tazarotene can be decreased when combined with Alpelisib.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Tazarotene.]
[G03DB05, demegestone, The therapeutic efficacy of Demegestone can be decreased when used in combination with Tazarotene.]
[G03AC09, desogestrel, The therapeutic efficacy of Desogestrel can be decreased when used in combination with Tazarotene.]
[N03AX25, cenobamate, The metabolism of Tazarotene can be increased when combined with Cenobamate.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Tazarotene.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Tazarotene.]
[G03DB08, dienogest, The therapeutic efficacy of Dienogest can be decreased when used in combination with Tazarotene.]
[M01AH02, rofecoxib, The metabolism of Tazarotene can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Tazarotene can be decreased when combined with Bexarotene.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Tazarotene.]
[L01EX22, selpercatinib, The serum concentration of Tazarotene can be increased when it is combined with Selpercatinib.]
[P01BA01, chloroquine, The metabolism of Tazarotene can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Tazarotene can be decreased when combined with Pralsetinib.]
[A02BA01, cimetidine, The metabolism of Tazarotene can be decreased when combined with Cimetidine.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Tazarotene.]
[B06AX04, mitapivat, The metabolism of Tazarotene can be increased when combined with Mitapivat.]
[H01CC04, linzagolix, The serum concentration of Tazarotene can be increased when it is combined with Linzagolix.]
[M09AX11, palovarotene, The risk or severity of adverse effects can be increased when Tazarotene is combined with Palovarotene.]
[L04AC21, bimekizumab, The metabolism of Tazarotene can be increased when combined with Bimekizumab.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Tazarotene.]
[L01EA01, imatinib, The metabolism of Tazarotene can be decreased when combined with Imatinib.]
[R06AX13, loratadine, The metabolism of Tazarotene can be decreased when combined with Loratadine.]
[L01AA01, cyclophosphamide, The metabolism of Tazarotene can be increased when combined with Cyclophosphamide.]
[J04BA02, dapsone, The metabolism of Tazarotene can be decreased when combined with Dapsone.]
[J01AA01, demeclocycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Demeclocycline.]
[L02BB02, nilutamide, The metabolism of Tazarotene can be decreased when combined with Nilutamide.]
[S03BA01, dexamethasone, The metabolism of Tazarotene can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Tazarotene can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Tazarotene can be increased when combined with Adalimumab.]
[N03AC01, paramethadione, The metabolism of Tazarotene can be decreased when combined with Paramethadione.]
[B01AC04, clopidogrel, The metabolism of Tazarotene can be decreased when combined with Clopidogrel.]
[S01BC03, diclofenac, The metabolism of Tazarotene can be decreased when combined with Diclofenac.]
[A10BG03, pioglitazone, The metabolism of Tazarotene can be decreased when combined with Pioglitazone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Tazarotene.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Tazarotene.]
[J05AE08, atazanavir, The metabolism of Tazarotene can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Tazarotene can be decreased when combined with Treprostinil.]
[C08DB01, diltiazem, The metabolism of Tazarotene can be decreased when combined with Diltiazem.]
[A03FA02, cisapride, The metabolism of Tazarotene can be decreased when combined with Cisapride.]
[S02AA12, rifamycin SV, The metabolism of Tazarotene can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Tazarotene can be increased when combined with Rifapentine.]
[S01BC05, ketorolac, The metabolism of Tazarotene can be decreased when combined with Ketorolac.]
[R03AC12, salmeterol, The metabolism of Tazarotene can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Tazarotene.]
[J01AA02, doxycycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Doxycycline.]
[C10AA01, simvastatin, The metabolism of Tazarotene can be decreased when combined with Simvastatin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Tazarotene.]
[C03CA04, torsemide, The metabolism of Tazarotene can be decreased when combined with Torasemide.]
[J01AA12, tigecycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Tigecycline.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Tazarotene.]
[N03AG01, valproic acid, Valproic acid may increase the Pseudotumor Cerebri activities of Tazarotene.]
[G03CA03, estradiol, The therapeutic efficacy of Estradiol can be decreased when used in combination with Tazarotene.]
[R03BA09, fluticasone furoate, The metabolism of Tazarotene can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Tazarotene can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Tazarotene can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Tazarotene.]
[R06AX12, terfenadine, The metabolism of Tazarotene can be decreased when combined with Terfenadine.]
[C08CA02, felodipine, The metabolism of Tazarotene can be decreased when combined with Felodipine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Tazarotene.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Tazarotene.]
[N05CF04, eszopiclone, The metabolism of Tazarotene can be decreased when combined with Eszopiclone.]
[C10AB04, gemfibrozil, The metabolism of Tazarotene can be decreased when combined with Gemfibrozil.]
[G03XA02, gestrinone, The therapeutic efficacy of Gestrinone can be decreased when used in combination with Tazarotene.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Tazarotene.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Tazarotene.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Tazarotene.]
[C09CA01, losartan, The metabolism of Tazarotene can be decreased when combined with Losartan.]
[C08CA10, nilvadipine, The metabolism of Tazarotene can be decreased when combined with Nilvadipine.]
[S02BA01, hydrocortisone, The metabolism of Tazarotene can be increased when combined with Hydrocortisone.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Tazarotene.]
[J04AB04, rifabutin, The metabolism of Tazarotene can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Tazarotene.]
[L01AA06, ifosfamide, The metabolism of Tazarotene can be increased when combined with Ifosfamide.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Tazarotene.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Tazarotene.]
[C10AA06, cerivastatin, The metabolism of Tazarotene can be decreased when combined with Cerivastatin.]
[L04AC07, tocilizumab, The metabolism of Tazarotene can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Tazarotene.]
[J02AB02, ketoconazole, The metabolism of Tazarotene can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Tazarotene can be decreased when combined with Levoketoconazole.]
[M02AA10, ketoprofen, The metabolism of Tazarotene can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Tazarotene can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Tazarotene can be increased when combined with Abatacept.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Tazarotene.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Tazarotene.]
[C10AA02, lovastatin, The metabolism of Tazarotene can be decreased when combined with Lovastatin.]
[J01AA04, lymecycline, The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Tazarotene.]
[G03DC03, lynestrenol, The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Tazarotene.]
[N03AB04, mephenytoin, The metabolism of Tazarotene can be decreased when combined with Mephenytoin.]
[J01AA05, methacycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Metacycline.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Tazarotene.]
[V04CG05, methylene blue, The metabolism of Tazarotene can be decreased when combined with Methylene blue.]
[P01AB01, metronidazole, The metabolism of Tazarotene can be decreased when combined with Metronidazole.]
[S02AA13, miconazole, The metabolism of Tazarotene can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Tazarotene.]
[G03XB01, mifepristone, The serum concentration of Tazarotene can be increased when it is combined with Mifepristone.]
[J01AA08, minocycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Minocycline.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Tazarotene.]
[N06AA09, amitriptyline, The metabolism of Tazarotene can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The metabolism of Tazarotene can be decreased when combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Tazarotene can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Tazarotene can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Tazarotene.]
[P01BA06, amodiaquine, The metabolism of Tazarotene can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Tazarotene can be decreased when combined with Raloxifene.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Tazarotene.]
[L04AC03, anakinra, The metabolism of Tazarotene can be increased when combined with Anakinra.]
[M02AA12, naproxen, The metabolism of Tazarotene can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Tazarotene can be decreased when combined with Troglitazone.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be decreased when combined with Tazarotene.]
[C08CA04, nicardipine, The metabolism of Tazarotene can be decreased when combined with Nicardipine.]
[G03DC02, norethindrone, The therapeutic efficacy of Norethisterone can be decreased when used in combination with Tazarotene.]
[G03AC07, norgestrienone, The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Tazarotene.]
[L04AC04, rilonacept, The metabolism of Tazarotene can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Tazarotene can be decreased when combined with Omeprazole.]
[S01AA04, oxytetracycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Oxytetracycline.]
[G03DB06, chlormadinone, The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Tazarotene.]
[N03AA02, phenobarbital, The metabolism of Tazarotene can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Tazarotene.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Tazarotene.]
[L04AB06, golimumab, The metabolism of Tazarotene can be increased when combined with Golimumab.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Tazarotene.]
[J05AE01, saquinavir, The metabolism of Tazarotene can be decreased when combined with Saquinavir.]
[S01BC06, piroxicam, The metabolism of Tazarotene can be decreased when combined with Piroxicam.]
[C09CA04, irbesartan, The metabolism of Tazarotene can be decreased when combined with Irbesartan.]
[A10BG02, rosiglitazone, The metabolism of Tazarotene can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Tazarotene.]
[L04AC08, canakinumab, The metabolism of Tazarotene can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The metabolism of Tazarotene can be decreased when combined with Ritonavir.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Tazarotene.]
[M04AB01, probenecid, The metabolism of Tazarotene can be increased when combined with Probenecid.]
[C10AB05, fenofibrate, The metabolism of Tazarotene can be decreased when combined with Fenofibrate.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Tazarotene.]
[R03DC03, montelukast, The metabolism of Tazarotene can be decreased when combined with Montelukast.]
[P01BD01, pyrimethamine, The metabolism of Tazarotene can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The metabolism of Tazarotene can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Tazarotene can be decreased when combined with Quinine.]
[J04AB02, rifampin, The metabolism of Tazarotene can be increased when combined with Rifampicin.]
[J01AA09, rolitetracycline, The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Rolitetracycline.]
[N05CA06, secobarbital, The metabolism of Tazarotene can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Tazarotene.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Tazarotene.]
[C03DA01, spironolactone, The metabolism of Tazarotene can be decreased when combined with Spironolactone.]
